Eupraxia Pharmaceuticals Inc. Common Stock (EPRX)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Eupraxia as a clinical-stage biotechnology company with 49 employees and two visible programs: EP-104IAR in Phase III for knee osteoarthritis and EP-104GI in Phase II for eosinophilic esophagitis. That is not a business with a moat yet; it is a research bet. Any durable advantage would have to come from successful trials, regulatory approvals, and eventual pricing power. The financials are not those of a mature compounder. At the $6.68 close on 2026-10-13, the market capitalization was $450.2 million. FairStock shows a P/E of -6.55, P/B of 4.31, ROE of -66.70%, and ROCE of -43.66%, all signs that current operations consume capital rather than produce it. Trailing free cash flow was -$38.2 million, a -8.5% FCF yield. The balance sheet has little leverage, with D/E of 0.01, and the Altman Z-Score of 25.53 suggests low measured distress, but a clinical-stage company can still need repeated financing. The Piotroski F-Score is 1/9 and the FairStock Score is 20/100, which is weak. Growth is entirely pipeline-dependent; no revenue growth figure is available, and the Lynch category is none because there are only 0 years of filed results versus the 3 needed. Graham would demand a margin of safety in assets and earnings. Here, book value is marked at 4.31 times, earnings are negative, and the value rests on unproven future events. I would call this speculative, not a bargain in the Graham sense.

In plain English: Eupraxia is a small clinical-stage drug developer with 49 employees. It does not yet have marketed products and is losing money, so the business looks weak on today's numbers. At the 2026-10-13 close of $6.68, the price looks expensive compared with its current financial results, and the value depends on future clinical trial success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer